JP2024547122A5 - - Google Patents
Info
- Publication number
- JP2024547122A5 JP2024547122A5 JP2024538148A JP2024538148A JP2024547122A5 JP 2024547122 A5 JP2024547122 A5 JP 2024547122A5 JP 2024538148 A JP2024538148 A JP 2024538148A JP 2024538148 A JP2024538148 A JP 2024538148A JP 2024547122 A5 JP2024547122 A5 JP 2024547122A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- sequence
- nos
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/140487 | 2021-12-22 | ||
| CN2021140487 | 2021-12-22 | ||
| PCT/CN2022/140958 WO2023116813A1 (en) | 2021-12-22 | 2022-12-22 | Anti-tnfr2 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024547122A JP2024547122A (ja) | 2024-12-26 |
| JP2024547122A5 true JP2024547122A5 (enExample) | 2026-01-06 |
Family
ID=86877889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538148A Pending JP2024547122A (ja) | 2021-12-22 | 2022-12-22 | 抗ｔｎｆｒ２抗体及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250019454A1 (enExample) |
| EP (1) | EP4453035A1 (enExample) |
| JP (1) | JP2024547122A (enExample) |
| KR (1) | KR20240123800A (enExample) |
| CN (2) | CN116333123A (enExample) |
| AU (1) | AU2022420151A1 (enExample) |
| CA (1) | CA3236748A1 (enExample) |
| WO (1) | WO2023116813A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116333123A (zh) * | 2021-12-22 | 2023-06-27 | 宝船生物医药科技(上海)有限公司 | 抗tnfr2抗体及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2742969A1 (en) * | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| CN115043943A (zh) * | 2015-05-15 | 2022-09-13 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
| US11859002B2 (en) * | 2016-05-13 | 2024-01-02 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor 2 antibodies |
| WO2018213064A1 (en) * | 2017-05-19 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting tnfer2 for cancer immunotherapy |
| EP3853252A1 (en) * | 2018-09-18 | 2021-07-28 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| JP7646542B2 (ja) * | 2018-11-01 | 2025-03-17 | バイオインベント インターナショナル アクティエボラーグ | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
| WO2021023098A1 (zh) * | 2019-08-02 | 2021-02-11 | 江苏先声药业有限公司 | 抗tnfr2抗体及其用途 |
| CA3154643A1 (en) * | 2019-09-17 | 2021-03-25 | Apexigen, Inc. | Anti-tnfr2 antibodies and methods of use |
| CN112480259B (zh) * | 2021-02-05 | 2021-05-04 | 百奥赛图(北京)医药科技股份有限公司 | 抗tnfr2抗体及其用途 |
| CN116333123A (zh) * | 2021-12-22 | 2023-06-27 | 宝船生物医药科技(上海)有限公司 | 抗tnfr2抗体及其用途 |
-
2022
- 2022-06-29 CN CN202210764994.9A patent/CN116333123A/zh active Pending
- 2022-12-22 US US18/712,043 patent/US20250019454A1/en active Pending
- 2022-12-22 KR KR1020247019500A patent/KR20240123800A/ko active Pending
- 2022-12-22 JP JP2024538148A patent/JP2024547122A/ja active Pending
- 2022-12-22 CA CA3236748A patent/CA3236748A1/en active Pending
- 2022-12-22 WO PCT/CN2022/140958 patent/WO2023116813A1/en not_active Ceased
- 2022-12-22 EP EP22910125.8A patent/EP4453035A1/en active Pending
- 2022-12-22 CN CN202280008094.XA patent/CN116848247B/zh active Active
- 2022-12-22 AU AU2022420151A patent/AU2022420151A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515318A5 (enExample) | ||
| JP2019501883A5 (enExample) | ||
| JP2020515239A5 (enExample) | ||
| JP2021510736A5 (enExample) | ||
| RU2019128134A (ru) | Антитело против gprc5d и молекула, содержащая антитело | |
| JP2020501531A5 (enExample) | ||
| JP2023549537A5 (enExample) | ||
| JP2024541680A5 (enExample) | ||
| JP2020500834A5 (enExample) | ||
| JP2022512642A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2023518153A5 (enExample) | ||
| IL276675B2 (en) | Anti-PD-1 antibodies and uses thereof | |
| JP2023549851A5 (enExample) | ||
| JP2022550243A5 (enExample) | ||
| JP2023549316A5 (enExample) | ||
| JP2023037000A5 (enExample) | ||
| JP2023517754A5 (enExample) | ||
| JP2023545521A5 (enExample) | ||
| JP2025503229A5 (enExample) | ||
| JP2024547122A5 (enExample) | ||
| JP2022513437A5 (enExample) | ||
| JP2024533457A5 (enExample) | ||
| JP2024540062A5 (enExample) | ||
| RU2024118627A (ru) | Антитела против tnfr2 и их применения |